A discovery funnel for nucleic acid binding drug candidates

Drug Development Research

Volumn 72, Issue 2, 2011, Pages 178-186

  Holt, Patrick A ^a   Buscaglia, Robert ^a   Trent, John O ^a   Chaires, Jonathan B ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

DNA; drug discovery; G quadruplex; high throughput screening; in silico screening; SURFLEX DOCK

Indexed keywords

GUANINE QUADRUPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER MODEL; DENATURATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DNA BINDING; DRUG RESEARCH; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY;

EID: 79953845513     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20414     Document Type: Article

References (58)

1. Baxter CA, Murray CW, Waszkowycz B, Li J, Sykes RA, Bone RG, Perkins TD, Wylie W,. 2000. New approach to molecular docking and its application to virtual screening of chemical databases. J Chem Inf Comput Sci 40: 254-262.
2. Brandts JF, Lin L-N,. 1990. Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 29: 6927-6940. (Pubitemid 20225495)
3. Burge S, Parkinson GN, Hazel P, Todd AK, Neidle S,. 2006. Quadruplex DNA: sequence, topology and structure. Nucleic Acids Res 34: 5402-5415. (Pubitemid 44742430)
4. Chaires JB,. 2008. Calorimetry and thermodynamics in drug design. Annu Rev Biophys 37: 135-151.
5. Chen Q, Shafer RH, Kuntz ID,. 1997. Structure-based discovery of ligands targeted to the RNA double helix. Biochemistry 36: 11402-11407. (Pubitemid 27408622)
6. Cuesta J, Read MA, Neidle S,. 2003. The design of G-quadruplex ligands as telomerase inhibitors. Mini Rev Med Chem 3: 11-21.
7. Darby RA, Sollogoub M, McKeen C, Brown L, Risitano A, Brown N, Barton C, Brown T, Fox KR,. 2002. High throughput measurement of duplex, triplex and quadruplex melting curves using molecular beacons and a LightCycler. Nucleic Acids Res 30: e39.
8. De Cian A, Cristofari G, Reichenbach P, De Lemos E, Monchaud D, Teulade-Fichou MP, Shin-Ya K, Lacroix L, Lingner J, Mergny JL,. 2007. Reevaluation of telomerase inhibition by quadruplex ligands and their mechanisms of action. Proc Natl Acad Sci USA 104: 17347-17352. (Pubitemid 350219845)
9. Detering C, Varani G,. 2004. Validation of automated docking programs for docking and database screening against RNA drug targets. J Med Chem 47: 4188-4201. (Pubitemid 39045426)
10. Drews J,. 2000. Drug discovery: a historical perspective. Science 287: 1960-1964. (Pubitemid 30158662)
11. Dror O, Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ,. 2009. Novel approach for efficient pharmacophore-based virtual screening: method and applications. J Chem Inf Model 49: 2333-2343.
12. Ekins S, Mestres J, Testa B,. 2007. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 152: 9-20. (Pubitemid 47339896)
13. Evans DA, Neidle S,. 2006. Virtual screening of DNA minor groove binders. J Med Chem 49: 4232-4238. (Pubitemid 44036666)
14. Garbett NC, Chaires JB,. 2008. Binding: a polemic and rough guide. Methods Cell Biol 84: 3-23.
15. Guedin A, Lacroix L, Mergny JL,. 2010. Thermal melting studies of ligand DNA interactions. Methods Mol Biol 613: 25-35.
16. Grootenhuis PD, Roe DC, Kollman PA, Kuntz ID,. 1994. Finding potential DNA-binding compounds by using molecular shape. J Computer-Aided Mol Design 8: 731-750.
17. Holt PA, Chaires JB, Trent JO,. 2008. Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex. J Chem Inf Model 48: 1602-1615.
18. Holt PA, Ragazzon P, Strekowski L, Chaires JB, Trent JO,. 2009. Discovery of novel triple helical DNA intercalators by an integrated virtual and actual screening platform. Nucleic Acids Res 37: 1280-1287.
19. Hopkins AL, Groom CR,. 2002. The druggable genome. Nat Rev Drug Discov 1: 727-730. (Pubitemid 37361545)
20. Hurley LH,. 2001. Secondary DNA structures as molecular targets for cancer therapeutics. Biochem Soc Trans 29: 692-696. (Pubitemid 33131762)
21. Hurley LH,. 2002. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 188-200. (Pubitemid 37328788)
22. Hurley LH, Wheelhouse RT, Sun D, Kerwin SM, Salazar M, Fedoroff OY, Han FX, Han H, Izbicka E, Von Hoff DD,. 2000. G-quadruplexes as targets for drug design. Pharmacol Ther 85: 141-158. (Pubitemid 30160784)
23. Hurley LH, Von Hoff DD, Siddiqui-Jain A, Yang D,. 2006. Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol 33: 498-512. (Pubitemid 44142743)
24. Imming P, Sinning C, Meyer A,. 2006. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5: 821-834. (Pubitemid 44480536)
25. Jenkins TC,. 2000. Targeting multi-stranded DNA structures. Curr Med Chem 7: 99-115. (Pubitemid 30395451)
26. Jorgensen WL,. 2004. The many roles of computation in drug discovery. Science 303: 1813-1818. (Pubitemid 38374866)
27. Kapetanovic IM,. 2008. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact 171: 165-176. (Pubitemid 351146652)
28. Kinnings SL, Jackson RM,. 2009. LigMatch: a multiple structure-based ligand matching method for 3D virtual screening. J Chem Inf Model 49: 2056-2066.
29. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE,. 1982. A geometric approach to macromolecule-ligand interactions. J Mol Biol 161: 269-288.
30. Le Doan T, Perrouault L, Praseuth D, Habhoub N, Decout JL, Thuong NT, Lhomme J, Helene C,. 1987. Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-[alpha]-thymidylate covalently linked to an azidoproflavine derivative. Nucleic Acids Res 15: 7749-7760.
31. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ,. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26. (Pubitemid 33653411)
32. Mergny JL, Lacroix L,. 2003. Analysis of thermal melting curves. Oligonucleotides 13: 515-537. (Pubitemid 38296149)
33. Mergny JL, Duval-Valentin G, Nguyen CH, Perrouault L, Faucon B, Rougee M, Montenay-Garestier T, Bisagni E, Helene C,. 1992. Triple helix-specific ligands. Science 256: 1681-1684.
34. Mergny JL, Helene C,. 1998. G-quadraplex DNA: a target for drug design. Nat Med 4: 1366-1367. (Pubitemid 28553455)
35. Mergny JL, Lacroix L, Teulade-Fichou MP, Hounsou C, Guittat L, Hoarau M, Arimondo PB, Vigneron JP, Lehn JM, Riou JF, Gavestier T, Helene C,. 2001. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc Natl Acad Sci USA 98: 3062-3067. (Pubitemid 32220799)
36. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E,. 2002. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 30: 839-865. (Pubitemid 34679653)
37. Monchaud D, Teulade-Fichou MP,. 2008. A hitchhiker's guide to G-quadruplex ligands. Org Biomol Chem 6: 627-636. (Pubitemid 351972601)
38. Moser HE, Dervan PB,. 1987. Sequence-specific cleavage of double helical DNA by triple helix formation. Science 238: 645-650. (Pubitemid 17158294)
39. Neidle S,. 1999. Oxford handbook of nucleic acid structure. New York: Oxford University Press.
40. Neidle S, Parkinson GN,. 2003. The structure of telomeric DNA. Curr Opin Struct Biol 13: 275-283. (Pubitemid 36782453)
41. Neidle S, Parkinson G,. 2002. Telomere maintenance as a target for anticancer drug discovery. Nat Rev Drug Discov 1: 383-393. (Pubitemid 37361468)
42. Neidle S, Read MA,. 2000. G-quadruplexes as therapeutic targets. Biopolymers 56: 195-208.
43. Neidle S, Thurston DE,. 2005. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 5: 285-296. (Pubitemid 40488634)
44. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, Carver T, Asel E, Springer BA, Lane P, Salemme FR,. 2001. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6: 429-440. (Pubitemid 34052847)
45. Patel DJ, Phan AT, Kuryavyi V,. 2007. Human telomere, oncogenic promoter and 5′-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics. Nucleic Acids Res 35: 7429-7455.
46. Praseuth D, Guieysse AL, Helene C,. 1999. Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim Biophys Acta 1489: 181-206.
47. Qin Y, Hurley LH,. 2008. Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. Biochimie 90: 1149-1171.
48. Rachwal PA, Fox KR,. 2007. Quadruplex melting. Methods 43: 291-301. (Pubitemid 47633208)
49. Ragazzon P, Chaires JB,. 2007. Use of competition dialysis in the discovery of G-quadruplex selective ligands. Methods 43: 313-323. (Pubitemid 47633211)
50. Ragazzon PA, Garbett NC, Chaires JB,. 2007. Competition dialysis: a method for the study of structural selective nucleic acid binding. Methods 42: 173-182. (Pubitemid 46654811)
51. Rester U,. 2008. From virtuality to reality-virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Dev 11: 559-568. (Pubitemid 351950850)
52. Schapira M, Raaka BM, Samuels HH, Abagyan R,. 2000. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 97: 1008-1013. (Pubitemid 30080803)
53. Sinden RR,. 1994. DNA structure and function. San Diego, CA: Academic Press. 398p.
54. Tondi D, Slomczynska U, Costi MP, Watterson DM, Ghelli S, Shoichet BK,. 1999. Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase. Chem Biol 6: 319-331. (Pubitemid 29363182)
55. Trent JO,. 2001. Advances in DNA molecular modeling. An update. Methods Enzymol 340: 290-326.
56. Yand D, Okamoto K,. 2010. Structural insights into G-quadruplexes: towards new anticancer drugs. Fut Med Chem 2: 619-646.
57. Zahler AM, Williamson JR, Cech TR, Prescott DM,. 1991. Inhibition of telomerase by G-quartet DNA structures. Nature 350: 718-720. (Pubitemid 21912306)
58. Zoete V, Grosdidier A, Michielin O,. 2009. Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 13: 238-248.